Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
paresh_vyas

Prof Paresh Vyas has just been awarded a Grant from Leukaemia and Lymphoma Research  - A first-in-human, first-in-class Phase I dose escalation trial of Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia (AML).

Paresh says – “Leukaemia and Lymphoma Research is one of the biggest charitable funders of haematology research in the UK.  They have awarded the MRC Molecular Haematology Unit a grant of £300 000 to conduct a first-in-class first in man clinical trial of a novel immunotherapeutic monoclonal antibody, directed against the cell surface protein CD47, to treat patients with relapsed/refractory Acute Myeloid Leukaemia.  This is an innovative therapeutic that aims to harness the body’s own immune system to fight cancer.  The work is a an exciting collaboration with the Oxford Early Phase Oncology Clinical Trials Unit, Stanford University and the UK AML Clinical Trials Group.“